Heidi Hagen Net Worth

The estimated Net Worth of Heidi Hagen is at least 511 千$ dollars as of 1 May 2024. Ms. Hagen owns over 3,200 units of Alaunos Therapeutics Inc stock worth over 16,226$ and over the last 10 years she sold ZIOP stock worth over 0$. In addition, she makes 494,697$ as Independent Director at Alaunos Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Hagen ZIOP stock SEC Form 4 insiders trading

Heidi has made over 7 trades of the Alaunos Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she exercised 3,200 units of ZIOP stock worth 2,784$ on 1 May 2024.

The largest trade she's ever made was buying 23,770 units of Alaunos Therapeutics Inc stock on 2 September 2021 worth over 41,835$. On average, Heidi trades about 2,651 units every 91 days since 2015. As of 1 May 2024 she still owns at least 18,650 units of Alaunos Therapeutics Inc stock.

You can see the complete history of Ms. Hagen stock trades at the bottom of the page.

Heidi Hagen biography

Heidi M. Hagen serves as Independent Director of the Company. Ms. Hagen has served as a member of our board since June 2019. Ms. Hagen has held the position of a biotechnology and pharmaceutical operations and technology consultant with HH Consulting LLC since October 2012. Since October 2015, Ms. Hagen has served as Co-founder and Advisor for Vineti, Inc., a privately-held company that develops and sells cloud-based software platforms for ordering, manufacturing and delivering personalized medicines. Previously, Ms. Hagen served as interim Chief Commercial Officer at ZappRx, Inc. from January 2015 to June 2015. Prior to that, Ms. Hagen served as Global Chief Operating Officer at Sotio LLC, a biotechnology company developing new therapies for the treatment of cancer and autoimmune diseases using its immunotherapy platform and proprietary cell-based technologies, from March 2013 to April 2014. Prior to joining Sotio, Ms. Hagen was Senior Vice President of Operations at Dendreon Corporation from 2002 to 2012, where she was responsible for, among other duties, manufacturing and supply chain operations. Prior to joining Dendreon, Ms. Hagen spent nearly ten years at Immunex Corporation, where she held several positions in drug development and supply chain and operations management. Ms. Hagen has served on the board of directors of Vericel Inc., a publicly-held company developing advanced cell therapies and specialty biologics for the sports medicine and severe burn care markets, since August 2013, and on the board of directors of Lykan Biosciences LLC, a privately held contract manufacturing company, since June 2019. Ms. Hagen earned her B.S. in cell and molecular biology, M.S. in bioengineering, and MBA at the University of Washington.

What is the salary of Heidi Hagen?

As the Independent Director of Alaunos Therapeutics Inc, the total compensation of Heidi Hagen at Alaunos Therapeutics Inc is 494,697$. There are 4 executives at Alaunos Therapeutics Inc getting paid more, with Laurence Cooper having the highest compensation of 3,317,570$.

How old is Heidi Hagen?

Heidi Hagen is 51, she's been the Independent Director of Alaunos Therapeutics Inc since 2019. There are 13 older and 3 younger executives at Alaunos Therapeutics Inc. The oldest executive at Alaunos Therapeutics Inc is J. Kevin Buchi, 65, who is the Director.

What's Heidi Hagen's mailing address?

Heidi's mailing address filed with the SEC is C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE, MA, 02139.

Insiders trading at Alaunos Therapeutics Inc

Over the last 19 years, insiders at Alaunos Therapeutics Inc have traded over 2,792,771$ worth of Alaunos Therapeutics Inc stock and bought 7,941,160 units worth 39,823,909$ . The most active insiders traders include Randal J Kirk、Randal Jintrexon Corp Kirk、Lindsay A Md Rosenwald. On average, Alaunos Therapeutics Inc executives and independent directors trade stock every 72 days with the average trade being worth of 152,086$. The most recent stock trade was executed by Groot Eleanor De on 22 December 2021, trading 20,132 units of ZIOP stock currently worth 25,568$.

What does Alaunos Therapeutics Inc do?

Ziopharm Oncology is an immuno-oncology company focused on developing end-to-endcost-effective solutions using its non-viralSleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 (IL-12). The Sleeping Beauty platform genetically modifies T cells with DNA plasmids to express T-cell receptors (TCRs) to target specific antigens in solid tumors and chimeric antigen receptors (CARs) to target CD19 in blood cancers with the Company's 3rd generation T-cell manufacturing process, rapid personalized manufacture (RPM). The Sleeping Beauty platform is being advanced in collaboration with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Eden BioCell. The Company also is developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including in collaboration with Regeneron Pharmaceuticals.

Complete history of Ms. Hagen stock trades at Vericel Corp、Alaunos Therapeutics Inc

Alaunos Therapeutics Inc executives and stock owners

Alaunos Therapeutics Inc executives and other stock owners filed with the SEC include:

• Laurence Cooper,
  Chief Executive Officer, Director
• Satyavrat Shukla,
  Chief Financial Officer
• Robert Hadfield,
  Executive Vice President, Chief Compliance Officer, General Counsel, Secretary
• Kevin Lafond,
  Senior Vice President - Finance, Chief Accounting Officer, Treasurer
• Heidi Hagen,
  Independent Director
• Dr. Eleanor de Groot Ph.D.,
  Exec. VP of Operations
• Christopher Bowden,
  Independent Director
• Scott Tarriff,
  Independent Chairman of the Board
• Dr. Raffaele Baffa M.D., Ph.D.,
  Chief Medical Officer and Exec. VP of R&D
• Elan Ezickson,
  Independent Director
• Zuie-Chin Huang M.B.A.,
  Exec. Chairman
• Mary Thistle,
  Independent Director
• Raffaele Baffa,
  Chief Medical Officer
• Christopher Taylor,
  Vice President, Investor Relations and Corporate Communications
• James Huang,
  Director
• J. Kevin Buchi,
  Director
• Lynn Ferrucci,
  Executive Vice President of Human Resources, Facilities, Administration and IT
• Eleanor De Groot,
  Executive Vice President, General Manager, Cell Therapy
• Jill Buck,
  Executive Vice President, General Manager, Gene Therapy
• Dr. Drew Deniger,
  Head of TCR-T Cell Therapy Program
• Dr. David M. Mauney M.D.,
  Consultant
• Melinda Lackey,
  Sr. VP of Legal
• Michael Wong,
  VP of Fin. & Principal Accounting Officer
• Timothy M. Cunningham CPA, M.B.A.,
  Interim CFO & Principal Financial Officer
• Kevin S. Boyle Sr.,
  CEO & Director
• James Anthony Cannon,
  Director
• Randal Jintrexon Corp Kirk,
  
• Murray Brennan,
  Director
• Wyche Fowler,
  Director
• Randal J Kirk,
  Director
• Caesar J Belbel,
  COO, CLO, and Secretary
• Michael Weiser,
  Director
• Francois Lebel,
  Executive Vice President R&D
• David M Md Mauney,
  President
• Douglas W. Pagan,
  Director
• Scott Braunstein,
  Director
• Hagop Youssoufian,
  Executive VP, CMO
• Timothy Mcinerney,
  Director
• Jonathan Lewis,
  CEO
• Jason Amello,
  Executive Vice President & CFO
• Richard E Bagley,
  President, COO & Treasurer
• George B Abercrombie,
  Director
• Robert Peter Gale,
  Senior V.P. of Research
• Lindsay A Md Rosenwald,
  10% owner
• Woodlands Health Ventures F...,
  10% owner
• Gary S Fragin,
  Director
• Sath Shukla,
  EVP, Chief Financial Officer
• Jaime Vieser,
  Director
• Holger Weis,
  Director
• Robert W Postma,
  Director
• Kevin S. Sr. Boyle,
  Chief Executive Officer
• Melinda Lackey,
  Senior Vice President, Legal